Publications by authors named "Volker Schettler"

Claim this Profile
L
Lipoprotein apheresis for lipoprotein(a)-associated progressive atherosclerotic cardiovascular disease: 12-years follow-up.
Reinhard Klingel, Ulrich Julius, Wanja M Bernhardt, Franz Heigl, Ralf Spitthoever, Volker J J Schettler

Atherosclerosis· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment persistence, lipid lowering, and 3-year clinical outcomes in patients at very high cardiovascular risk on PCSK9 monoclonal antibodies.
Klaus G Parhofer, David Pittrow, Andreas L Birkenfeld, Uwe Fraass, Bernd Hohenstein, Volker J J Schettler

Clin Res Cardiol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Determinants of lipid lowering therapy intensification in very high risk patients with dyslipidaemia eligible for PCSK9 monoclonal antibodies: 1-year outcomes of the PERI-DYS study.
Klaus G Parhofer, David Pittrow, Andreas L Birkenfeld, Uwe Fraass, Bernd Hohenstein, Volker J J Schettler

Acta Cardiol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effective exosomes reduction in hypercholesterinemic patients suffering from cardiovascular diseases by lipoprotein apheresis: Exosomes apheresis.
Sophie Schröder, Robert Epple, Andre Fischer, Volker J J Schettler

Ther Apher Dial· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evolocumab-Based LDL-C Management in High and Very High Cardiovascular Risk Patients in German Clinical Practice: The HEYMANS Study.
Michael Lehrke, Anja Vogt, Volker Schettler, Matthias Girndt, Uwe Fraass

Adv Ther· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel Insights into the Management of Patients with Very High Cardiovascular Risk Eligible for PCSK9 Inhibitor Treatment: Baseline Findings from the PERI-DYS Study.
Ulrich Laufs, Andreas L Birkenfeld, Uwe Fraass, Bernd Hohenstein, Carsten Siegert, Volker J J Schettler

Cardiovasc Drugs Ther· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[State of the art: lipoprotein apheresis].
Ulrike Schatz, Volker J J Schettler, Ulrich Julius

Dtsch Med Wochenschr· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Correction: State of the art: lipoprotein apheresis].
Ulrike Schatz, Volker J J Schettler, Ulrich Julius

Dtsch Med Wochenschr· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Beyond cholesterol-pleiotropic effects of lipoprotein apheresis.
Volker J J Schettler, Elke Schettler

Ther Apher Dial· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The German Lipoprotein Apheresis Registry-Summary of the ninth annual report.
Volker J J Schettler, Christian Peter, Thomas Zimmermann, Ulrich Julius, Eberhard Roeseler

Ther Apher Dial· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
With reasonable doubt: Plasma exchange in PEXIVAS.
Bernd Hohenstein, Volker Schettler, Kirsten de Groot

Ther Apher Dial· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lipoprotein(a) - Marker for cardiovascular risk and target for lipoprotein apheresis.
Reinhard Klingel, Franz Heigl, Volker Schettler, Eberhard Roeseler, Peter Grützmacher

Atheroscler Suppl· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lipoprotein apheresis in Germany - Still more commonly indicated than implemented. How can patients in need access therapy?
Franz Heigl, Tobias Pflederer, Reinhard Klingel, Reinhard Hettich, Norbert Lotz, Volker J J Schettler

Atheroscler Suppl· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NMR-based lipoprotein analysis for patients with severe hypercholesterolemia undergoing lipoprotein apheresis or PCSK9-inhibitor therapy (NAPALI-Study).
Volker Jj Schettler, Florian Muellendorff, Elke Schettler, Christina Platzer, Sabine Norkauer

Ther Apher Dial· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world study: Escalating targeted lipid-lowering treatment with PCSK9-inhibitors and lipoprotein apheresis.
Ralf Spitthöver, Tilmann Röseler, Ulrich Julius, Franz Heigl, Volker J J Schettler

J Clin Apher· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Toward an international consensus-Integrating lipoprotein apheresis and new lipid-lowering drugs.
Claudia Stefanutti, Ulrich Julius, Gerald F Watts, Mariko Harada-Shiba, Maria Cossu, Volker J Schettler

J Clin Lipidol· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of lipid reduction with DALI and MONET.
Wolfgang Ramlow, Eberhard Röseler, Franz Heigl, Ralf Spitthöver, Jens Ringel, Volker Schettler

Atheroscler Suppl· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety aspects of lipidapheresis using DALI and MONET - Multicenter observational study.
Justyna Kozik-Jaromin, Eberhard Röseler, Franz Heigl, Ralf Spitthöver, Jens Ringel, Volker Schettler

Atheroscler Suppl· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lipidological competence centres and networks: Future perspectives to improve healthcare of patients with disorders of lipid metabolism.
Franz Heigl, Tobias Pflederer, Volker Schettler, Peter Grützmacher, Ulrich Julius

Atheroscler Suppl· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Significance of Monoclonal PCSK9-Antibodies - New Approaches to the Therapy of Hypercholesterolemia.
Claas L Neumann, Elke Schettler, Volker J J Schettler

Blood Purif· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial.
Patrick M Moriarty, Klaus G Parhofer, Stephan P Babirak, Marc-Andre Cornier, P Barton Duell, Volker Schettler

Eur Heart J· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First data from the German Lipoprotein Apheresis Registry (GLAR).
Volker J J Schettler, Class L Neumann, Christian Peter, Thomas Zimmermann, Ulrich Julius

Atheroscler Suppl· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of the German Lipoprotein Apheresis Registry (DLAR) on therapeutic options to reduce increased Lp(a) levels.
Volker J J Schettler, Class L Neumann, Christian Peter, Thomas Zimmermann, Ulrich Julius

Clin Res Cardiol Suppl· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term effects of 3-month telemetric blood pressure intervention in patients with inadequately treated arterial hypertension.
Claas L Neumann, Jan Menne, Volker Schettler, Gerrit C Hagenah, Christiane Brockes

Telemed J E Health· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Successful completion of pregnancy using apheresis and a balanced dose of coagulation factors in the presence of high thrombophilia and Lp(a) levels in a woman with two previous abortions.
Volker J J Schettler, Egbert G Schulz, Gerrit C Hagenah, Claas L Neumann

Clin Kidney J· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis